-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From left to right: Marselina Arshakyan, Elba Marín (front), Paula Duch, Cristina Teixidó, Noemí regart, Rafael Ikemori, Jordi Alcaraz, Marta Gabasa and Natalia Díaz
Levels of the TIMP-1 protein in tissues and blood have been repeatedly shown to be associated with a poor prognosis for lung cancer, but its role in this cancer process remains unclear to this day
"In recent decades, cancer research has aimed at providing more specific treatments for each type of tumor and patient, improving patient outcomes
The study included the participation of researchers from
A unique collection of fibroblasts of Spanish patient origin
TIMP-1 is a protein abnormally secreted by fibroblasts, a non-malignant cell that accompanies cancer cells and is a major component of the so-called tumor microenvironment
Interaction of Protumour with CD63 receptors
The results first suggested that elevated TIMP-1 levels in lung cancer were due to the "pathological level" at which fibroblasts secreted this protein
New treatment strategies
These results may facilitate the development
In this sense, the study, in addition to showing that fibroblasts play a very important role in tumor progression, also opens up a way to "attack this tumor axis": so-called anti-fibrotic drugs, developed to inhibit the pathological function
Effects on other cancers
These results may also be effective for other cancers, as the TIMP-1 protein is also widely described as a biomarker of poor prognosis in many types of solid tumors
